Live Markets
Wednesday, July 29, 2026·George Town, KY·29°·Partly Cloudy
Markets Open · NYSE·Newsletter·Masthead·
VOL. XII · NO. 117Established MMXIV · George Town, Grand CaymanAtlantic Edition · $4.50

The Cayman Journal

Finance · Business · Technology · Caribbean & Global Affairs
Markets · Healthcare

Tandem Diabetes Care, Inc. (TNDM)

NGM · Medical Devices

$17.76+0.59 (+3.44%)Quote refreshed

Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires

Market Cap
$1.22B
P/E (TTM)
EPS
$-1.42
Div Yield
52W Range
$9.98–$29.65
Beta
1.58

Company overview

Next earnings: 2026-08-06(9d)

Tandem Diabetes Care, Inc. designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. It's flagship products are the t:slim X2 insulin delivery system; and Tandem Mobi insulin pump, an automated insulin delivery system. The company also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, it offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company has collaboration agreement with the University of Virginia Center for Diabetes Technology for research and development of fully automated closed-loop insulin delivery systems. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.

Peers in Medical Devices

All in industry →

Recent press releases

April 2026

3 months agoDEF 14AHealthcare

TNDM Shareholders Vote on Executive Pay After $1 Billion Sales

TNDMTANDEM DIABETES CARE INC

# 🧾 What This Document Is This is a **proxy statement** (DEF 14A), a formal document public companies must send to shareholders before an annual meeting. Think of it as the agenda and information packet for that meeting. 👉 **Why it matters:** It tells you what shareholders will vote on, who is on

Read summaryView on SEC EDGAR

SEC filings

All filings →
1 recent filing shown in the timeline above. View all SEC filings →

Tandem Diabetes Care, Inc. has no reported insider trades in the last 90 days.

Institutional holders

All holders →
As of 2025-12-31 · prior 2025-09-30
11,149,181 sh-7.9%
7,341,356 sh+3.9%
5,000,000 sh0.0%
2,152,003 sh+1451.5%
2,080,497 sh+182.1%
1,610,342 sh● NEW
2,021,376 sh+42.3%
1,227,856 sh● NEW

People at Tandem Diabetes Care, Inc.

All people →

Quarterly financials

Full financials →
Revenue trend
03/25
$150.6M
NI -$130.6M
06/25
$240.7M
NI -$52.4M
09/25
$249.3M
NI -$21.2M
RevenueNI = Net Income
EPS trend (diluted)
Latest: $-0.31
Prior: $-0.78
Revenue sparkline